Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Aurum Biosciences, a UK-based acute ischaemic stroke treatment spinout of University of Glasgow and public health board NHS Greater Glasgow and Clyde, has received around £670,000 ($875,000) in equity funding from investors including Scottish Health Innovations, the commercialisation arm of national healthcare provider NHS Scotland, Pharmiweb reported on Monday. The round also featured vertically-integrated drug developer Infinion Biopharma, angel syndicate Tricapital and unnamed additional investors. The cash follows a $4.5m equity and convertible debt round in 2015 involving Scottish Investment Bank, a subsidiary of government-owned Scottish Enterprise, charitable foundation Wellcome Trust, Tricapital and unnamed additional investors.
